An Evaluation of Multisense® to Ensure a Safe Return Home Following High-risk Gastrointestinal Surgery, Compared With Standard Care.
SENSE-ECO
Clinical and Health Economic Evaluation of the Multisense® Solution: Ensuring a Safe Return Home for Patients at High Risk of Complications Following Gastrointestinal Surgery, Compared With the Standard Care Pathway.
1 other identifier
interventional
490
1 country
5
Brief Summary
The SENSE-ECO study is a prospective, randomized trial of 490 high-risk patients designed to show that the MultiSense® remote monitoring patch safely reduces hospital stays following major digestive surgery. By continuously tracking vital signs for five days at home, the device aims to maintain clinical safety and quality of life while decreasing overall healthcare costs for the French medical system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2026
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2026
CompletedFirst Posted
Study publicly available on registry
April 27, 2026
CompletedStudy Start
First participant enrolled
May 18, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 17, 2027
Study Completion
Last participant's last visit for all outcomes
November 19, 2027
April 27, 2026
April 1, 2026
1.3 years
March 31, 2026
April 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Mean CCI score of the Detailed Complications Index, calculated on the basis of complications recorded according to the Clavien-Dindo classification over a 30 day postoperative period for each of the two groups: the MultiSense group and Standard group
The Clavien-Dindo classification is a system used in surgery to classify postoperative complications according to their severity
30 days
The average length of the initial stay for both groups
Up to 30 days
Secondary Outcomes (13)
Average CCI score from the Detailed Complications Index, calculated based on complications recorded according to the Clavien-Dindo classification over 8days, 15days, 30days and 90days post-surgery for each of the two groups: MultiSense® grp & Standad grp
8days, 15days, 30days and 90days
Average number of deaths in each arm over 8 days, 15 days, 30 days and 90 days
8 days, 15 days, 30 days and 90 days
Average total cumulative length of stay over 30 days
30 days
Average number of hospital readmissions among patients receiving MultiSense® compared with patients receiving standard care, over a 30 days period; severity of the patient at readmission assessed using the Clavien-Dindo classification
30 days
Patient quality of life scores assessed at baseline, on discharge from hospital and at 30 days using the fQoR-15 questionnaire
30 days
- +8 more secondary outcomes
Study Arms (2)
MultiSense® group
EXPERIMENTALPatients wearing the multisense® patch
Standard group
NO INTERVENTIONPatients following the standard care pathway
Interventions
The MultiSense device will be placed on the patient's back and will allow physicians to remotely monitor six biological parameters
Eligibility Criteria
You may qualify if:
- Adults (aged 18 and over)
- Patients scheduled for gastrointestinal surgery :
- Major gastrointestinal cancer surgery (pancreas, liver, stomach, oesophagus, rectum)
- Colorectal surgery (rectal resection, surgery on the rectum and anus other than rectal resection, minor or major surgery on the small intestine and colon)
- Patients in non-critical care with a high risk of post-surgical complications (ASA score 2 or 3)
- Patients who have a personal mobile phone and Wi-Fi connectivity at home
- Patients who provide written informed consent to participate in the study
- Patients who are members of or beneficiaries of a social security scheme
- Patients who are proficient in French
You may not qualify if:
- Patients with a contraindication to the use of the device as described in the instructions for use (in particular: known skin allergy to adhesives or silicone, active implantable medical device such as a pacemaker or defibrillator, need for an MRI scan during the intended use of the device, intended application site of the device being tattooed, infected, ulcerated or damaged)
- Any other condition which, in the investigator's opinion, would compromise the patient's safety or prevent compliance with the requirements of the protocol
- Pregnant or breastfeeding patient
- Adult under legal protection (under guardianship, curatorship or judicial protection)
- Patient already participating in a clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rhythm Diagnostic Systemslead
- Calypsecollaborator
- BPIfrancecollaborator
Study Sites (5)
CHU de Nice
Nice, Alpes-Maritimes, 06000, France
CHU de Besançon
Besançon, Doubs, 25000, France
CHU Charles-Nicolle
Rouen, Seine-Maritime, 76000, France
CHU Amiens-Picardie
Amiens, 80000, France
Hôpital Cochin, AP-HP Centre
Paris, 75014, France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 31, 2026
First Posted
April 27, 2026
Study Start (Estimated)
May 18, 2026
Primary Completion (Estimated)
September 17, 2027
Study Completion (Estimated)
November 19, 2027
Last Updated
April 27, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share